In conclusion, H.C. Wainwright’s analyst expressed confidence in Moonlake Immunotherapeutics’ trajectory, restating a 12-month price target of $100 per share.

Investing.com -- The yields on government bonds in the Euro zone increased on Monday as the United States withdrew its threat to impose 50% tariffs on European imports, which eased concerns over a ...

The aircraft with the former tail number TC-ATA was transferred from the Prime Ministry to the Presidency of Defence Industry in 2016. Its tail number was changed to TC-GVA, and in 2017 it was sold at ...

Mining activities in the region have caused landslides and forced citizens to migrate from the Maden district of Elazığ, but projects continue undeterred. Last year, Cengiz Holding initiated plans to ...

S&P/TSX Composite Index 26,269.00 195.87 0.75% ...